Loading...
XSES
P8A
Market cap70mUSD
Aug 03, Last price  
0.36SGD
Name

Cordlife Group Ltd

Chart & Performance

D1W1MN
XSES:P8A chart
P/E
P/S
3.26
EPS
Div Yield, %
Shrs. gr., 5y
0.13%
Rev. gr., 5y
-9.47%
Revenues
28m
-50.04%
25,673,00030,275,00034,702,00049,087,00042,764,94659,627,00059,962,00068,309,00060,331,63445,795,56044,631,33241,997,39555,156,00055,730,00027,843,000
Net income
-19m
L
8,476,0006,926,00013,484,00030,521,00024,106,94312,329,000-2,572,0003,272,0001,776,6754,812,4044,953,6564,546,6484,887,0003,523,000-18,686,000
CFO
-11m
L
8,035,0006,033,0008,665,0003,667,0000-4,010,0001,972,0008,966,00010,209,0009,841,22213,078,3498,891,7175,944,0009,796,000-11,312,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

As an investment holding company, Cordlife Group Limited offers cord blood banking solutions across various countries including Singapore, Hong Kong, India, Malaysia, and the Philippines, extending its reach globally. Its operations are structured into two distinct segments: Banking and Diagnostics. The Banking segment is dedicated to the processing and secure storage of stem cells derived from cord blood, cord lining, and cord tissue. Meanwhile, its Diagnostics arm delivers a suite of screening services, such as non-invasive prenatal testing, pediatric vision evaluations, and genetic and metabolic screenings for newborns. Furthermore, Cordlife extends its diagnostic offerings to include specialized procedures like preimplantation genetic screening, endometrial receptivity testing, pediatric allergen analysis, and genetic talent assessments. It also supports parents through "moms up," a mobile application providing valuable resources for pregnancy and parenting. Beyond its core medical services, the company engages in management, marketing, and property investment activities. Established in 2001, Cordlife Group Limited maintains its corporate headquarters in Singapore.
IPO date
Mar 29, 2012
Employees
Domiciled in
SG
Incorporated in
SG

Valuation

Title
SGD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT